Search

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded lower 3% as Truist downgraded the shares to hold from buy amid a delay in the close of its planned purchase of Alimera Sciences [...]

ATLANTA: Alimera Sciences, Inc. has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

ENPNewswire-August 7, 2024--Alimera Sciences Reports Second Quarter 2024 Results (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 06082024 - ATLANTA - Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose [...]

Net Revenue up 54% to $27 Million vs. Q2 2023 Global End User Demand up 6% vs. Q2 2023 Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, [...]

PRINCETON: ANI Pharmaceuticals, Inc. announced they have signed a definitive agreement under which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value [...]

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue [...]

Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May [...]

Scope: EyePoint Pharmaceuticals will build an advanced cGMP facility in Northbridge, to manufacture eye disorders treatment, by the second half of 2024. EyePoint Pharmaceuticals, a US-based pharmaceutical company, will expand [...]

Alimera Sciences, Inc. (Alimera) has announced its financial results for the fourth quarter and full year 2023. The company's net revenue increased by 88% to approximately $26.3 million in Q4 [...]

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE [...]

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces that [...]

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Alimera Sciences, Inc. has completed enrollment for the Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in treating chronic [...]

ENPNewswire-November 2, 2023--EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 01112023 - WATERTOWN - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), [...]

- Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic [...]

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced [...]

Net Revenue up 72% to $23.4 Million vs. Q3 2022 Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022 Adjusted EBITDA of $5.4 Million in Q3 2023 Successful [...]

ATLANTA: Alimera Sciences, Inc. has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Alimera Acquired U.S. Commercial Rights to YUTIQ [sup. (R) ] Landmark NEW DAY Study Completed Enrollment with over 300 Patients Consolidated Net Revenue of $17.5 Million Up 20% vs. Second [...]

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced financial [...]

-Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 - -Phase 2 PAVIA clinical trial evaluating [...]

- Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer - - Nancy S. Lurker Transitions to Executive Vice Chair of the Board [...]

Redwood City, California: Gunderson Dettmer Stough Villeneuve Franklin & Hachigian has issued the following press release: Gunderson Dettmer represented client Alimera Sciences, a global pharmaceutical company, in its acquisition of [...]

ATLANTA: Alimera Sciences, Inc. has issued the following press release: Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following press release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with [...]

ENPNewswire-May 19, 2023--EyePoint Pharmaceuticals Announces Sale of YUTIQ to Alimera Sciences, Inc. for $82.5 Million Cash plus Royalties (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 18052023 - WATERTOWN - EyePoint Pharmaceuticals, [...]